Yael A Leshem1, Joanne R Chalmers2, Christian Apfelbacher3, Masutaka Furue4, Louise A A Gerbens5, Cecilia A C Prinsen6, Jochen Schmitt7, Phyllis I Spuls5, Kim S Thomas2, Hywel C Williams2, Eric L Simpson8. 1. Divison of Dermatology, Rabin Medical Center, Petach-Tikva, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. Electronic address: yael.leshem@gmail.com. 2. Centre of Evidence-Based Dermatology, University of Nottingham, Nottingham, United Kingdom. 3. Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany; Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany. 4. Department of Dermatology, Kyushu University, Fukuoka, Japan. 5. Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands. 6. Amsterdam UMC, VU University, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands. 7. Center for Evidence-based Healthcare, Medical Faculty Carl Gustav Carus, Dresden, Germany. 8. Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
Abstract
BACKGROUND: Measuring patient-centered outcomes in clinical practice is valuable for monitoring patients and advancing real-world research. A new initiative from the Harmonising Outcome Measures for Eczema (HOME) group aims to recommend what might be recorded for atopic eczema patients in routine clinical care. OBJECTIVES: Prioritize outcome domains to measure atopic eczema in clinical practice and select valid and practical outcome measurement instruments for the highest-priority domain. METHODS: An online survey of HOME members identified and ranked 21 possible health domains. Suitable instruments were then selected for the top-prioritized domain at the HOME VI meeting, using established consensus processes informed by systematic reviews of instrument quality. RESULTS: Patient-reported symptoms was the top-prioritized domain. In accordance with psychometric properties and feasibility, there was consensus that the recommended instruments to measure atopic eczema symptoms in clinical practice are the POEM, the PO-SCORAD index, or both. The numeric rating scale for itch received support pending definition and validation in atopic eczema. CONCLUSION: Following the first step of the HOME Clinical Practice initiative, we endorse using the POEM, the PO-SCORAD index, or both for measuring atopic eczema symptoms in clinical practice. Additional high-priority domains for clinical practice will be assessed at subsequent HOME meetings.
BACKGROUND: Measuring patient-centered outcomes in clinical practice is valuable for monitoring patients and advancing real-world research. A new initiative from the Harmonising Outcome Measures for Eczema (HOME) group aims to recommend what might be recorded for atopic eczemapatients in routine clinical care. OBJECTIVES: Prioritize outcome domains to measure atopic eczema in clinical practice and select valid and practical outcome measurement instruments for the highest-priority domain. METHODS: An online survey of HOME members identified and ranked 21 possible health domains. Suitable instruments were then selected for the top-prioritized domain at the HOME VI meeting, using established consensus processes informed by systematic reviews of instrument quality. RESULTS:Patient-reported symptoms was the top-prioritized domain. In accordance with psychometric properties and feasibility, there was consensus that the recommended instruments to measure atopic eczema symptoms in clinical practice are the POEM, the PO-SCORAD index, or both. The numeric rating scale for itch received support pending definition and validation in atopic eczema. CONCLUSION: Following the first step of the HOME Clinical Practice initiative, we endorse using the POEM, the PO-SCORAD index, or both for measuring atopic eczema symptoms in clinical practice. Additional high-priority domains for clinical practice will be assessed at subsequent HOME meetings.
Authors: Nicholas Shortt; Alexander Martin; Kyley Kerse; Gabrielle Shortt; Iva Vakalalabure; Luke Barker; Joseph Singer; Bianca Black; Angela Liu; Allie Eathorne; Mark Weatherall; Marius Rademaker; Mike Armour; Richard Beasley; Alex Semprini Journal: EClinicalMedicine Date: 2022-07-15
Authors: Jonathan I Silverberg; Eric L Simpson; Mark Boguniewicz; Marjolein S De Bruin-Weller; Peter Foley; Yoko Kataoka; Gaëlle Bégo-Le-Bagousse; Zhen Chen; Brad Shumel; Jingdong Chao; Ana B Rossi Journal: Acta Derm Venereol Date: 2021-11-10 Impact factor: 3.875
Authors: Lawrence F Eichenfield; Stephen Stripling; Selwyn Fung; Amy Cha; Andryann O'Brien; Lawrence A Schachner Journal: Paediatr Drugs Date: 2022-06-13 Impact factor: 3.930
Authors: Marjolein De Bruin-Weller; Tilo Biedermann; Robert Bissonnette; Mette Deleuran; Peter Foley; Giampiero Girolomoni; Jana Hercogová; Chih-Ho Hong; Norito Katoh; Andrew E Pink; Marie-Aleth Richard; Stephen Shumack; Juan F Silvestre; Stephan Weidinger Journal: Acta Derm Venereol Date: 2021-02-17 Impact factor: 3.875
Authors: M J Cork; A McMichael; J Teng; H Valdez; R Rojo; G Chan; F Zhang; D E Myers; M DiBonaventura Journal: J Eur Acad Dermatol Venereol Date: 2021-12-04 Impact factor: 9.228